BP PHARMA HOLDING ApS

APSIn liquidation

CVR 35038825Mosestedet 53, 3500 VærløseEconomic activity was not specified by tax authority· NACE 0000Est. 2013 · 13 years old— employees

Overview

BP PHARMA HOLDING ApS is a Danish APS based in Værløse, operating in the Economic activity was not specified by tax authority sector. Incorporated in 2013, the company reported a gross profit of DKK 20.0k in its latest annual filing.

Gross profit 2014

0M DKK

−71% vs 2013

EBITDA margin (of gross profit)

100.0 %

0% vs 2013

Net profit 2014

0.6M DKK

0% vs 2013

Key ratios

See full ratios →

28.0 %

Very weak

Among the 20% lowest rated companies in the industry

20132014

0.1×

Very weak

Among the 10% lowest rated companies in the industry

20132014

24.7 %

Very strong

Among the 10% highest rated companies in the industry

20132014

EBITDA — year on year

DKK thousands

Key figures

Annual report 2014

Gross profit	0M DKK	-71%
EBITDA	0M DKK	0%
Net profit	0.6M DKK	0%
Total assets	2.4M DKK	0%
Equity	0.7M DKK	0%
Employees	—	—

Financial development

In its most recent annual report (2014), BP PHARMA HOLDING ApS reported a gross profit of DKK 20.0k, a decrease of 71% on the year before. The figures on this page draw on 2 annual filings covering 2013 to 2014. The bottom line showed a net profit of DKK 605.8k, and the EBITDA margin stood at 100%.

At the end of 2014, equity financed 28% of the balance sheet, and current assets covered short-term debt 0.1 times.

Financials

Revenue

DKK thousands

EBITDA

DKK thousands

Income statement

DKK thousands

Item	2014	2013
Revenue	20	69
Staff expenses	-0	-0
EBITDA	20	20
Depreciation & amort.	9	-9
EBIT	11	11
Net financials	584	584
Profit before tax	617	617
Tax	11	11
Net profit	606	606

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

DKK thousands

Item	2014	2013
Total assets	2,448	2,448
Equity	686	686
Long-term debt	667	0
Short-term debt	1,763	1,763
Total debt	1,763	1,763

Financial ratios

5-year trend

EBITDA margin

100.0 %

20132014

Equity ratio

28.0 %

Very weak

Among the 20% lowest rated companies in the industry

20132014

Return on equity

88.3 %

Very strong

Among the 10% highest rated companies in the industry

20132014

Net profit margin

>999 %

20132014

Asset turnover

0.01×

20132014

Debt / equity

2.57×

Very weak

Among the 10% lowest rated companies in the industry

20132014

Sector performance

23 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Return on equity (ROE)Very strong

Among the 10% highest rated companies in the industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Very strong

Among the 10% highest rated companies in the industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Very strong

Among the 10% highest rated companies in the industry

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Strong

Among the 30% highest rated companies in the industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Capacity ratioVery strong

Among the 20% highest rated companies in the industry

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Gross marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Liquidity

Current ratioVery weak

Among the 10% lowest rated companies in the industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioVery weak

Among the 20% lowest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioVery weak

Among the 10% lowest rated companies in the industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityStrong

Among the 30% highest rated companies in the industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalVery weak

Among the 10% lowest rated companies in the industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioAverage

Around the average of companies in the same industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Solidity ratioVery weak

Among the 20% lowest rated companies in the industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioVery weak

Among the 20% lowest rated companies in the industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Debt to equityVery weak

Among the 10% lowest rated companies in the industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityVery weak

Among the 10% lowest rated companies in the industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtAverage

Around the average of companies in the same industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtStrong

Among the 30% highest rated companies in the industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest coverageStrong

Among the 30% highest rated companies in the industry

The ability to pay the interest on the company's debt out of its earnings.

Interest rate on debtAverage

Around the average of companies in the same industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginVery strong

Among the 20% highest rated companies in the industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Efficiency & development

Equity to contributed capitalWeak

Among the 40% lowest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityWeak

Among the 40% lowest rated companies in the industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtStrong

Among the 40% highest rated companies in the industry

The size of this year's increase or decrease in the company's debt.

Asset turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2014
Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
View PDF
Annual report 2013
Filed via CVR / Virk · Period 2013-01-25 – 2013-12-31
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since

Former (3)


BS Birgit Søndergaard Pedersen Founder	Founder	2013 – 2016
CB Claus Bærentzen Management	Management	2013 – 2015
UM Ulrik Møller Liquidator	Liquidator	2015 – 2016

Board of directors

Non-executive oversight

No data on file.

Shareholders

Active legal owners

Shareholder	Type	Ownership	Votes	Registered
Birgit Søndergaard Pedersen	Individual	50–66.65%	50–66.65%	2013
Claus Bærentzen	Individual	50–66.65%	50–66.65%	2013

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

No registered parent or subsidiaries

Board network connections

Board members of BP PHARMA HOLDING ApS also hold positions in 4 other companies.

Person	Role here	Other companies
Ulrik Møller	Liquidator	4 companies

Frequently asked questions

What is the CVR number of BP PHARMA HOLDING ApS?

BP PHARMA HOLDING ApS is registered with CVR / Virk under CVR 35038825.

What is the gross profit of BP PHARMA HOLDING ApS?

BP PHARMA HOLDING ApS reported a gross profit of DKK 20.0k in 2014.

Where is BP PHARMA HOLDING ApS headquartered?

BP PHARMA HOLDING ApS's registered address is Mosestedet 53.